Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Abstract

BACKGROUND Ivonescimab is a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor, yielding promising clinical outcomes for patients with advanced non-small cell lung cancer in early-phase studies. We compared the efficacy and safety of ivonescimab with pembrolizumab in patients with programmed cell death ligand-1 (PD-L1)-positive advanced non-small cell lung cancer. METHODS HARMONi-2 is a randomised, double-blind, phase 3 trial across 55 hospitals in China. Eligible patients were aged 18 years or older and had locally advanced or metastatic PD-L1-positive non-small cell lung cancer without sensitising epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations and an Eastern Cooperative Oncology Group performance-status of 0 or 1. Patients were randomly assigned (1:1) to receive 20 mg/kg ivonescimab or 200 mg pembrolizumab intravenously every 3 weeks. Randomisation was stratified by histology, clinical stage, and PD-L1 expression. The primary endpoint was progression-free survival (PFS) assessed by a masked independent radiographic review committee per RECIST v1.1 in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT05499390; recruitment is complete, with the trial ongoing and final analysis to be reported later. FINDINGS Between Nov 9, 2022, and Aug 26, 2023, 398 (45%) of 879 screened patients were randomly assigned to receive ivonescimab (n=198) or pembrolizumab (…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)02722-3

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 22 references

Cited by

See all 207

Metadata

Authors
Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., Ge, H., Yao, J., Shi, Q., Zhou, M., Chen, B., Han, Z., Wang, J., Bu, Q., Zhao, Y., Chen, J., Nie, L., Li, G., Li, X., Yu, X., Ji, Y., Sun, D., Ai, X., Chu, Q., Lin, Y., Hao, J., Huang, D., Zhou, C., Shan, J., Yang, H., Liu, X., Wang, J., Shang, Y., Mei, X., Yang, J., Lu, D., Hu, M., Wang, Z. M., Li, B., Xia, M., & Zhou, C.
Affiliations
  • Tongji University (CN)
  • Hunan Cancer Hospital (CN)
  • Third Affiliated Hospital of Harbin Medical University (CN)
  • Fourth Hospital of Hebei Medical University (CN)
  • Shanghai Chest Hospital (CN)
  • Gannan Medical University (CN)
  • Jilin Province Tumor Hospital (CN)
  • Shandong Tumor Hospital (CN)
  • Guangzhou Medical University Cancer Hospital (CN)
  • Chinese PLA General Hospital (CN)
  • First Affiliated Hospital of GuangXi Medical University (CN)
  • Henan Cancer Hospital (CN)
  • Peking University First Hospital (CN)
  • First Affiliated Hospital of Zhengzhou University (CN)
  • Zhejiang Cancer Hospital (CN)
  • First Affiliated Hospital of Xinxiang Medical University (CN)
  • Tianjin Chest Hospital (CN)
  • First Affiliated Hospital of University of South China (CN)
  • Tongji Hospital (CN)
  • First Affiliated Hospital of Anhui Medical University (CN)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Army Medical University (CN)
  • Changsha Central Hospital (CN)
  • Third Xiangya Hospital (CN)
  • Affiliated Hospital of Hebei University (CN)
  • Anhui Provincial Hospital (CN)
Corresponding author
Zhou, Caicun
Venue
The Lancet
Publisher
Elsevier BV
Published
2025-03
Volume
405
Issue
10481
Pages
839-849
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4408177149
Cited by
173
References
22
Citations by year
2026: 97 · 2025: 76
FWCI
71.64
Type
journal article
Language
en
Update notices
erratum (2025-11-01)
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
ivonescimab, pembrolizumab, PD-L1-positive non-small cell lung cancer, bispecific antibodies, vascular endothelial growth factor, PD-1 inhibitors, progression-free survival, immune checkpoint inhibitors, metastatic lung cancer, China, subgroup analysis, safety and tolerability, adverse events
MeSH terms
Antineoplastic Agents, Immunological, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Carcinoma, Non-Small-Cell Lung, China, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Antibodies, Bispecific, B7-H1 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. https://app.cochat.ai/papers/10.1016/s0140-6736(24)02722-3
The paper
Xiong, A., Wang, L., Chen, J., Wu, L., Liu, B., Yao, J., Zhong, H., Li, J., Cheng, Y., Sun, Y., Ge, H., Yao, J., Shi, Q., Zhou, M., Chen, B., Han, Z., Wang, J., Bu, Q., Zhao, Y., . . . Zhou, C. (2025). Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. The Lancet. https://doi.org/10.1016/s0140-6736(24)02722-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.